N
Neon Therapeutics
Focused on unlocking the full potential of the immune system to recognize and attack cancer
About Neon Therapeutics
Neon Therapeutics, a company acquired by BioNTech in 2020, operated in the immuno-oncology sector with a focus on developing neoantigen-targeted therapies for cancer treatment. The company was founded in 2013 by a distinguished group of individuals including Nir Hacohen, Stephen Hoge, Eric Lander, Robert Langer, James Allison, Ton Schumacher, and Pardis Sabeti, emerging from stealth mode in 2015. This team brought together extensive expertise in genomics, immunology, and drug delivery, which was foundational to the company's scientific approach.
The core of Neon Therapeutics' strategy was the development of personalized cancer treatments. Their lead candidate, NEO-PV-01, was a personal cancer vaccine custom-designed for each patient based on the unique neoantigens—mutations found exclusively on cancer cells. This vaccine was intended to be used in combination with checkpoint inhibitors to stimulate a tailored immune response against a patient's specific tumor. The company also developed a T-cell therapy program, NEO-PTC-01, which involved extracting, selecting, and expanding a patient's own T-cells that were naturally reactive to their cancer's neoantigens. Beyond personalized therapies, Neon Therapeutics was also advancing a shared neoantigen program, targeting common mutations found across certain cancer patient populations.
Financially, Neon Therapeutics achieved several significant milestones. The company raised a total of $241 million through various funding rounds, including a $106 million Series B financing in 2017. It went on to successfully launch an Initial Public Offering (IPO) in June 2018, raising $100 million. Ultimately, the company's journey culminated in its acquisition by BioNTech in May 2020 for $67 million, a move that integrated Neon's neoantigen expertise and its US-based team into BioNTech's global operations.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 61.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Drug Development, Core AI, Spinout, Tech for Biotech and Pharma, Biotech and Pharma, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jan 2020 | $67M | $67M | BioNTech | — |
| IPOOther financing | Jun 2018 | $100M | $451M | Undisclosed | — |
Growth signals
Latest recorded traffic for Neon Therapeutics is 110 monthly website visits, down 47.6% over the last three months. Neon Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Neon Therapeutics in the Cambridge ecosystem
The Neon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Third Rock Ventures
Clal Biotechnology Industries
Access Industries
PFM Health Sciences- NVNextech Venture
Fidelity Investments
Hillhouse Capital
Casdin Capital
Wellington Management- APArrowMark Partners
Other known investors4 additional known investors
BioNTech
Broad Institute
Dana-Farber Cancer Institute
Massachusetts General Hospital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neon Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









